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Abstract
Background: The agouti protein is a paracrine factor that is normally present in the skin of many species of mammals.
Agouti regulates the switch between black and yellow hair pigmentation by signalling through the melanocortin 1
receptor (Mc1r) on melanocytes. Lethal yellow (Ay) and viable yellow (Avy) are dominant regulatory mutations in the mouse
agouti gene that cause the wild-type protein to be produced at abnormally high levels throughout the body. Mice
harboring these mutations exhibit a pleiotropic syndrome characterized by yellow coat color, obesity, hyperglycemia,
hyperinsulinemia, and increased susceptibility to hyperplasia and carcinogenesis in numerous tissues, including the liver.
The goal of this research was to determine if ectopic expression of the agouti gene in the liver alone is sufficient to
recapitulate any aspect of this syndrome. For this purpose, we generated lines of transgenic mice expressing high levels
of agouti in the liver under the regulatory control of the albumin promoter. Expression levels of the agouti transgene in
the liver were quantified by Northern blot analysis. Functional agouti protein in the liver of transgenic mice was assayed
by its ability to inhibit binding of the α-melanocyte stimulating hormone (αMSH) to the Mc1r. Body weight, plasma insulin
and blood glucose levels were analyzed in control and transgenic mice. Control and transgenic male mice were given a
single intraperitoneal injection (10 mg/kg) of the hepatocellular carcinogen, diethylnitrosamine (DEN), at 15 days of age.
Mice were euthanized at 36 or 40 weeks after DEN injection and the number of tumors per liver and total liver weights
were recorded.
Results: The albumin-agouti transgene was expressed at high levels in the livers of mice and produced a functional agouti
protein. Albumin-agouti transgenic mice had normal body weights and normal levels of blood glucose and plasma insulin,
but responded to chemical initiation of the liver with an increased number of liver tumors compared to non-transgenic
control mice.
Conclusions: The data demonstrate that liver-specific expression of the agouti gene is not sufficient to induce obesity
or diabetes, but, in the absence of these factors, agouti continues to promote hepatocellular carcinogenesis.
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Background
The wild-type agouti coat color exhibited by many mammals consists of individual hairs that are black with a subterminal band of yellow [1]. The mouse agouti gene product is a secreted paracrine factor that regulates the alternate production of black and yellow pigments produced
by hair-bulb melanocytes [2-4]. Binding of αMSH to the
Mc1r on the surface of hair-bulb melanocytes results in
the production of black pigment that is deposited in the
growing hair. The agouti gene is transiently expressed in
the skin during the mid-portion of the hair growth cycle.
At this time, the agouti protein binds to the Mc1r, thereby
excluding αMSH binding and causing a switch from black
to yellow pigment production by melanocytes, which
results in the appearance of the sub-terminal yellow band
in the otherwise black hair [5-10].
Recessive mutations in the agouti gene affect only the coat
color of mice, causing either a partial or complete loss of
yellow pigment in the hair [11,12]. The dominant agouti
mutations, lethal yellow (Ay) and viable yellow (Avy), affect
coat color by causing an increase in the amount of yellow
pigment in the hair. Additionally, these dominant mutations cause mice to develop type II diabetes (peripheral
insulin resistance, pancreatic islet hypertrophy and hyperplasia, hyperinsulinemia, and hyperglycemia), obesity
(hyperphagia and increased adipose mass), increased
somatic growth (increased fat-free dry mass and slightly
longer bones), and increased susceptibility to hyperplasia
and carcinogenesis in numerous tissues [reviewed in refs.
[13-22]]. This syndrome is manifested in lethal yellow and
viable yellow mice because they carry regulatory mutations
in the agouti gene that cause the normal protein to be produced at abnormally high levels throughout the body [2326].
In addition to its normal role of regulating pigmentation
through Mc1r, agouti can also antagonize αMSH binding
to other melanocortin receptor family members [5,2731]. The ability of agouti to antagonize binding of αMSH
to the Mc4r is of particular relevance, as Mc4r is expressed
in the brain and mice lacking functional Mc4r are hyperinsulinemic, hyperphagic, and obese [32]. Mutations in
human MC4R were also identified in dominantly inherited forms of human obesity [33,34]. These results suggest
that the hyperinsulinemia, hyperphagia, and obesity in
lethal yellow and viable yellow mice is caused primarily by
agouti-induced antagonism of Mc4r in the hypothalamus,
a center of autonomic regulatory control in the brain [35].
In addition to a role in the central nervous system, agouti
expression in adipose tissue also appears to contribute to
the obesity syndrome. Transgenic mice with adipocytespecific agouti expression were shown to have significantly
increased fat mass compared to control mice, which was
accompanied by an increase in the protein levels of three
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transcription factors (Pparg, peroxisome proliferator activated receptor gamma; Stat1, signal transducer and activator of transcription 1; and Stat3) in their adipose tissue
[36]. These three transcription factors were also upregulated in mature 3T3-L1 adipocytes in culture following
treatment with recombinant agouti protein [36]. Additionally, recombinant agouti protein causes an increase in
fatty acid synthase expression and activity, and the accumulation of triglycerides in cultured adipocytes [37].
Together, these results suggest that the obesity-related factors of the dominant agouti syndrome are mediated by
agouti expression in both the brain and peripheral
tissue(s).
Dominant mutations in the agouti gene also cause an
increase in the susceptibility to hyperplasia and carcinogenesis in the liver [38-45], skin [46,47], lung [44,48-50],
mammary gland [38,39,51-54], and urinary bladder [55].
It is likely that agouti-mediated antagonism of melanocortin receptors is mainly responsible for the obesity and
diabetes of lethal yellow and viable yellow mice, but it is not
known if melanocortin receptors are involved in their
increased susceptibility to cancer. Whereas the obesityrelated factors may contribute to the increased predisposition to carcinogenesis, there is some evidence to support
the hypothesis that ectopic expression of the agouti gene
per se may promote carcinogenesis in the liver and lung,
even in the absence of hyperinsulinemia and obesity [44].
The liver is a primary site of insulin-mediated glucose disposal and lipogenesis in the mouse. Based on this fact,
and on the previous reports of increased susceptibility to
hepatic carcinogenesis in dominant agouti mutant mice,
we were interested in determining if agouti expression in
the liver alone would be sufficient to induce any of the
phenotypes observed in lethal yellow or viable yellow mice.
For this purpose, we generated lines of transgenic mice in
which the wild-type murine agouti cDNA was expressed
only in the liver at levels similar to or greater than those
observed in lethal yellow or viable yellow mice. Transgenic
and control mice were compared with respect to body
weights, blood glucose levels, plasma insulin levels, and
tumorigenic responses to chemical initiation in the liver.

Results
The albumin promoter directs expression of the wild-type
agouti cDNA to the liver in transgenic mice
The albumin promoter was used to direct liver-specific
expression [56] of the wild-type murine agouti cDNA in
transgenic mice. Three lines of transgenic mice were established and two of these lines were characterized in detail:
FVB/N-Tg(Alb1-a)86R and FVB/N-Tg(Alb1-a)83R (hereafter referred to as alb-agouti 86 and alb-agouti 83, respectively). As expected, agouti expression was detected only in
the liver of the transgenic mice after an agouti cDNA probe
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was hybridized to Northern blots containing ~2.5 µg of
poly (A)+ RNA from adult muscle, liver, small intestine,
brain and white adipose tissue. The expression level of
agouti in the liver of an alb-agouti 86 mouse is compared
to that of a BAPa20 mouse (FVB/N-TgN(BAPa)20Rpw) in
Figure 1. BAPa20 is a line of transgenic mice in which the
wild-type agouti cDNA is under the regulatory control of
the human β-actin promoter and enhancer. It was previously demonstrated that BAPa20 mice express the agouti
gene in a ubiquitous manner and, consequently, become
hyperinsulinemic and obese [57]. As seen in Figure 1, albagouti 86 mice express the agouti cDNA in the liver at a
higher level than do BAPa20 mice.
The expression levels of agouti in the livers of alb-agouti
86 and 83 transgenic mice was next estimated by densitometry and compared to the levels of agouti expressed in
the livers of BAPa20, lethal yellow (Ay/a), and viable yellow
(Avy/a) mice (Fig. 2). Viable yellow mice have coat colors
ranging from completely yellow (y) to mottled yellow and
agouti (m) to pseudoagouti (p), and the amount of yellow pigment in the coat is correlated with the level of
agouti expression throughout the body and the severity of
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Estimate of agouti expression levels in the livers of
alb-agouti 86, alb-agouti 83, BAPa20, lethal yellow
(Ay/a) and viable yellow (Avy/a) mice. A Northern blot of
poly (A)+ RNA, isolated from the liver of a single mouse for
each of the genotypes indicated, was hybridized with a radiolabeled agouti cDNA probe, then stripped and rehybridized
with a radiolabeled Gapd cDNA probe to control for the
amount of mRNA loaded for each sample. Levels of agouti
mRNA relative to Gapd mRNA levels were quantified for
each sample by densitometric analysis (see Methods). The
level of agouti mRNA expression in lethal yellow mice was
assigned the value of 1.0, and the expression levels in viable
yellow mice and transgenic mice were normalized relative to
this value. The viable yellow mice used in this assay had coat
colors that were completely yellow (y), mottled yellow and
agouti (m), or pseudoagouti (p).

the obesity, diabetes, and neoplasia that they display [16].
The alb-agouti 86 mice express agouti in the liver at ~13.7
times the level in lethal yellow liver, and at a level that is
also substantially greater than in BAPa20 liver and the livers of all three phenotypic classes of viable yellow mice. In
contrast, the alb-agouti 83 mice express agouti in the liver
at ~0.8 times the level in lethal yellow liver, at approximately one third the level in BAPa20 liver, but still at a
greater level than in the livers of all three classes of viable
yellow mice. Thus, under the hypothesis that expression of
agouti in the liver alone is sufficient to induce the obesity
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mice. Liver homogenates from non-transgenic control
mice and liver homogenates from non-transgenic control
mice spiked with recombinant agouti protein were treated
in the same manner. Relative inhibition of [125I]-NDPαMSH binding to the Mc1r for each of the three samples
is displayed in Figure 3. The alb-agouti 86 sample inhibited [125I]-NDP-αMSH binding in the assay almost as
effectively as the control sample spiked with recombinant
agouti protein, whereas the control sample from nontransgenic mice did not significantly affect αMSH
binding.
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Analysis of functional agouti protein in the liver of
alb-agouti 86 transgenic mice. Functional agouti protein
was assayed by its ability to inhibit binding of [125I]-NDPαMSH to the Mc1r in murine melanoma B16F10 cells. The
livers from three alb-agouti 86 mice were excised, pooled,
homogenized, and enriched for agouti protein. The livers
from three non-transgenic control mice were treated in the
same manner (see Methods). The B16F10 cells were incubated for 2 hr at room temperature with 0.1 nM [125I]-NDPαMSH plus increasing amounts of either partially purified
liver homogenate from control mice (control), liver homogenate from alb-agouti 86 mice (alb-agouti 86), or liver
homogenate from control mice spiked with recombinant
agouti protein (control+agouti). Bound radioactive ligand was
measured and plotted (y-axis) against the amount of liver
homogenates used in the assay (x-axis).

and diabetes of viable yellow mice, both lines of alb-agouti
transgenic mice express the wild-type agouti cDNA in the
liver at levels that should be adequate to induce these
effects.
alb-agouti transgenic mice produce functional agouti
protein in the liver
Recombinant murine agouti protein inhibits the binding
of [125I]-NDP-αMSH to the Mc1r in B16F10 murine
melanoma cells. This assay was used as previously
described [58,59] to determine if the alb-agouti transgene
produces a functional agouti protein in the liver of the
transgenic mice. Prior to the assay, an S Sepharose chromatography procedure was used to enrich for agouti protein in liver homogenates from alb-agouti 86 transgenic

alb-agouti transgenic mice have normal body weight, and
normal levels of plasma insulin and blood glucose
To determine if expression of the agouti gene in the liver
alone is sufficient to induce obesity and diabetes, the
body weight, and levels of blood glucose and plasma insulin were analyzed in the alb-agouti transgenic mice and
compared to those of non-transgenic siblings. There were
no significant differences (p > 0.05) in body weight
between transgenic and control mice fed a diet containing
11% fat by weight (Fig. 4). Levels of plasma insulin and
blood glucose did not differ significantly (p > 0.05)
between the alb-agouti transgenic mice and the non-transgenic controls, whereas both insulin and glucose levels
were significantly elevated in BAPa20 mice (positive controls) as expected (Table 1). Therefore, these data indicate
that expression of the agouti gene in the liver alone is not
sufficient to induce obesity or diabetes.
alb-agouti transgenic mice respond to chemical initiation
of the liver with an increased number of tumors per liver
To determine if the presence of agouti in the livers of albagouti 83 and 86 transgenic mice promotes liver carcinogenesis in the absence of obesity and diabetes, a single
intraperitoneal injection of the liver carcinogen, DEN (10
mg/kg body weight), was administered to transgenic and
control male mice at 15 days of age. Body weights of all
injected mice were recorded from 4–42 weeks of age, and
there were no significant differences (p > 0.05) between
either of the transgenic lines and their non-transgenic littermates at any time point (data not shown). Three mice
from each of the transgenic and control groups were euthanized at various times after DEN injection, and it was
determined that 36 and 40 weeks post-injection were the
most appropriate times for sampling the mice, because
tumors at those ages were macroscopically visible and had
not yet coalesced (data not shown). Therefore, separate
groups of transgenic and control mice (n = 18–20 per
group) were euthanized at 36 weeks or 40 weeks postinjection, and their tumor numbers and liver weights were
recorded (Fig. 5).

At 36 weeks after DEN injection, the number of tumors
per liver was 2.3 ± 0.4 (mean ± one standard error of the
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correlated with the level of agouti expression in the liver.
Whereas transgenic mice had more tumors per liver than
did the control mice, the size distribution of tumors was
similar in transgenics and controls (data not shown). The
fact that alb-agouti 86 mice have normal body weights
and levels of blood glucose and plasma insulin, but
responded to DEN with significantly more liver tumors
than did the non-transgenic mice demonstrates a more
direct effect of agouti in the promotion of liver
carcinogenesis.
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termate
rates of alb-agouti transgenic mice and wild-type litGrowth rates of alb-agouti transgenic mice and wildtype littermate controls. Body weights of alb-agouti 86
(A) and alb-agouti 83 (B) mice were recorded once every
four weeks from 4–36 weeks of age and compared to littermate control mice. Shown are the means ± one standard
error of the mean (for many of the means, the standard
errors are too small to see the error bars). Sample sizes
range from 6–22 for each mean. The weights of transgenic
and control mice did not differ significantly (p > 0.05) at any
time.

mean) for the controls, 3.5 ± 0.7 for alb-agouti 83, and 4.0
± 0.9 for alb-agouti 86 (Figure 5A). Both lines of transgenic mice had a greater number of liver tumors than did
the controls at 36 weeks, but these differences were not
statistically significant (Tukey-Kramer multiple-comparison test at α = 0.05). At 40 weeks after DEN injection, the
mean number of tumors per liver for the controls, and the
alb-agouti 83 and 86 mice was 4.1 ± 1.1, 6.8 ± 1.6, and
10.4 ± 2.5, respectively (Figure 5A). At this time, the mean
number of tumors for the alb-agouti 86 mice differed significantly (p < 0.05) from the controls, but not from the
alb-agouti 83 mice. The mean number of tumors for the
alb-agouti 83 mice did not differ significantly from the
controls (p > 0.05). At both 36 and 40 weeks, the number
of tumors per liver for the transgenic mice was positively

Total liver weight was also recorded at 36 and 40 weeks
after DEN injection. Both lines of transgenic mice had
greater average liver weights than did the control mice (Fig
5B). The differences in liver weights between alb-agouti
86 mice and controls were significant (p < 0.05) at both 36
weeks (1.95 g ± 0.06 vs. 1.63 g ± 0.07) and 40 weeks (1.97
g ± 0.08 vs. 1.67 g ± 0.03) after DEN injection, whereas the
differences between alb-agouti 83 mice and controls were
not significant (p > 0.05). Unlike the livers from obese
lethal yellow and viable yellow mice, where visual examination reveals an excessive amount of fat deposition in the
liver (E. J. M., personal observations), the livers from lean
alb-agouti 83 and 86 mice did not appear to be different
from control livers in terms of fat content (data not
shown). This suggests that the heavier livers in DEN
injected alb-agouti transgenic mice resulted from agouti
protein-induced hyperplasia and/or greater tumor burdens, not of an increased triglyceride content of the liver.

Discussion
The current investigations were undertaken to determine
if agouti expression in the liver of transgenic mice could
recapitulate any aspects of the dominant pleiotropic syndrome (i.e., obesity, hyperglycemia, hyperinsulinemia,
and/or liver cancer) observed in lethal yellow and viable yellow mice. To address this question, lines of transgenic
mice were generated in which the wild-type agouti cDNA
was ectopically expressed only in the liver under the regulatory control of the albumin promoter. Different lines of
transgenic mice were shown to express the agouti gene in
the liver at levels that were similar to or greater than the
levels detected in the livers of mice that express agouti
ubiquitously and exhibit the pleiotropic syndrome (lethal
yellow, viable yellow, and BAPa20 mice).
Although the liver is a key lipogenic tissue in the mouse
and a major site of glucose disposal (conversion to glycogen), the finding that body weight, blood glucose and
plasma insulin did not differ significantly between the
alb-agouti transgenic and control mice demonstrates that
agouti expression in the liver alone is insufficient to induce
obesity, hyperglycemia or hyperinsulinemia. However,
expression of agouti in the livers of the transgenic mice did
cause an increase in the susceptibility to DEN-induced
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Table 1: Circulating glucose and insulin concentrations in transgenic and control micea

Line
alb-agouti 83
alb-agouti 86
BAPa20

Blood glucose (mg/dl)
controls
transgenics
116 ± 8 (5)
115 ± 12 (5)
122 ± 12 (5)

115 ± 7 (5)
112 ± 7 (5)
241 ± 37 (8)*

Plasma insulin (µU/ml)
controls
transgenics
32 ± 3 (10)
26 ± 3 (6)
31 ± 6 (5)

28 ± 3 (6)
32 ± 3 (11)
197 ± 33 (9)*

aData are presented as the mean ± one standard error of the mean. Numbers in parentheses indicate sample sizes. Asterisks denote significant
differences between transgenic and control mice (p < 0.05).

liver carcinogenesis. The total tumor burden in the livers
of the exposed mice was estimated by considering both
the numbers of tumors visible on the surface of the livers
and the total weights of the livers. Thus, whereas the albagouti 86 transgenic mice had significantly more liver
tumors than control mice at 40, but not 36, weeks after
injection, the transgenic livers were significantly heavier
than the control livers at both time points (Fig. 5). Taken
together, these results indicate that the agouti protein
stimulated a significant increase in liver hyperplasia and/
or tumor burden of the alb-agouti 86 transgenic mice at
the earlier time point (36 weeks) as well.
The present observation that agouti has a primary role in
promoting liver carcinogenesis, independent of obesity
and diabetes, is in agreement with previous findings on
viable yellow mice [44]. Viable yellow mice express the
agouti gene in a ubiquitous manner, but exhibit a wide
range in the level of expression of the gene and the associated phenotypes. At one end of the spectrum are
individuals with very high levels of ubiquitous agouti
expression; these mice have completely yellow coats, and
they are obese and hyperinsulinemic. At the other end of
the spectrum are mice with very low levels of ubiquitous
agouti expression; these mice have coat colors that appear
almost normal (called pseudoagouti), and they have normal body weights and levels of circulating insulin. Mice in
the middle of the spectrum exhibit a moderate level of
ubiquitous agouti expression, have coats that are a patchwork of yellow and agouti hairs (i.e., mottled), and are
likely to become obese and hyperinsulinemic. Wolff and
colleagues [44] fed viable yellow mice and control mice a
diet supplemented with lindane (γ-hexachlorocyclohexane) for 24 months, then examined the mice for the development of tumors. They found that both the yellow mice
(obese and hyperinsulinemic) and the pseudoagouti mice
(lean and normoinsulinemic) had a higher prevalence of
chemically initiated liver and lung tumors (i.e., a greater
number of mice with tumors) than did control mice.
Tumor prevalence, however, was highest in the yellow
mice. Thus, a key discovery of these experiments, and of
particular relevance to this study, was that a very low level
of ubiquitous agouti expression did not cause obesity or

hyperinsulinemia, but was sufficient to promote carcinogenesis in some tissues. The higher prevalence of liver
tumors in pseudoagouti mice than in control mice
suggested that the tumor promoting effect of agouti was a
direct consequence of agouti expression in the liver. However, because pseudoagouti mice express the agouti gene in
a ubiquitous manner, albeit at a low level, it remained a
possibility that this low-level ubiquitous expression of
agouti may have elicited some other physiological
response that was in turn responsible for the tumor phenotype. The fact that a low level of constitutive agouti
expression in the skin of pseudoagouti mice is sufficient to
cause a subtle alteration in coat color [60] lends credence
to this possibility. The alb-agouti transgenic mice presented here have agouti expressed only in the liver and,
although they are lean and normoinsulinemic, are
predisposed to an increased number of liver tumors. In
fact, the number of tumors per liver in the transgenic mice
was correlated with their level of agouti expression in the
liver. These results demonstrate that agouti expression in
the liver is sufficient to promote liver carcinogenesis,
independent of any other apparent agouti-mediated physiological effects.
The molecular mechanism underpinning the role of the
agouti protein in promoting liver carcinogenesis is currently unknown. Whether agouti promotes carcinogenesis
by antagonizing a melanocortin receptor in the liver, or by
acting in a melanocortin-independent manner remains to
be determined. In this regard, it is interesting to note that
the only melanocortin receptor currently known to be
expressed in a widespread manner, including in the liver,
is Mc5r [61-63], but agouti protein appears to have little
to no effect on antagonizing the binding of αMSH to Mc5r
[5,64]. Whether agouti antagonizes the interaction of a
different ligand with the Mc5r is not known. The data presented here set the stage for future studies aimed at elucidating the mechanism of action of the agouti gene in the
promotion of hepatocellular hyperplasia and neoplasia.

Conclusions
In summary, we have demonstrated that liver-specific
expression of the agouti gene in transgenic mice was insuf-
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Agouti expression construct
An agouti expression construct (plasmid AlbPE-a) containing the murine albumin promoter and enhancer, the wildtype murine agouti cDNA, and the simian virus 40 (SV40)
polyadenylation sequences was generated as follows. A
ClaI fragment containing the agouti cDNA and SV40 polyadenylation sequences was isolated from plasmid clone
BAPa [57]. The ClaI ends were filled in with Klenow and
SalI linkers were ligated to the fragment [65]. The SalI fragment was then cloned into the SalI site of plasmid NB0.3
alb [56], downstream of the albumin promoter and
enhancer to generate the plasmid AlbPE-a. This expression
construct was verified by DNA sequencing. The AlbPE-a
plasmid was digested with SacI and KpnI to excise the 3.5kb expression cassette from vector sequences for microinjection into fertilized mouse eggs.

1.5

1
36

40

Weeks after DEN injection
Figure
Mean
control
tiation
number
with
and
5 DEN
alb-agouti
of tumors
transgenic
per livermice
and total
following
liver chemical
weights ininiMean number of tumors per liver and total liver
weights in control and alb-agouti transgenic mice following chemical initiation with DEN. Control, albagouti 83, and alb-agouti 86 male mice were each given a single intraperitoneal injection of DEN (10 mg/kg) at 15 days of
age. Mice were euthanized at either 36 or 40 weeks after
DEN injection and the mean number of tumors per liver (A)
and mean total liver weights (B) were determined for each
group. Shown are the means ± one standard error of the
mean. Sample sizes range from 18–20 for each group. Asterisks indicate significant difference from the controls (p <
0.05).

ficient to alter body weight, blood glucose level, or plasma
insulin level, but it did promote DEN-initiated liver
carcinogenesis. Because alb-agouti transgenic mice developed more liver tumors than did the control mice, the
expression of the agouti gene in the liver alone, in the
absence of obesity and diabetes, is sufficient to promote
the development of liver tumors in mice. These data suggest that the increased susceptibility of lethal yellow and

Transgenic mice
The pronuclei of fertilized eggs from a random-bred
closed-colony stock of FVB/N mice were microinjected
with the AlbPE-a expression cassette, along with a tyrosinase minigene expression cassette [66] (at a total DNA
concentration of 3 ng/µl in 10 mM Tris-HCl, 0.1 mM
EDTA, pH 7.5), to generate lines of transgenic mice as
described [67].

The tyrosinase expression cassette [66] produces pigmentation in the hair of albino FVB/N mice. Cointegration of
the AlbPE-a and tyrosinase expression cassettes permits
visual identification of the alb-agouti transgenic mice by
their coat color. Genomic DNA was obtained by tail
biopsy and all mice were genotyped for inheritance of the
AlbPE-a transgene by probing Southern blots of BamHIdigested DNA with an agouti cDNA probe, as described
[2]. Transgenic founder mice were mated to wild-type
FVB/N mice to establish independent transgenic lines,
and mice were maintained hemizygous for the transgene
by mating transgene carriers to FVB/N mice and genotyping the offspring by Southern blot analysis. For those lines
in which the AlbPE-a transgene was shown to cosegregate
with coat color, the mice were thereafter genotyped by
coat color with confirmation by Southern blotting a few
mice at each generation. All experiments involving mice
in this study were conducted under approved Institutional
Animal Care and Use Committee protocols.

Page 7 of 10
(page number not for citation purposes)

Molecular Cancer 2004, 3

Northern blot analysis
Isolation of total RNA and poly (A)+ RNA, preparation of
Northern blots, radiolabeling of hybridization probes,
and hybridization conditions were as described [68]. In
order to quantify levels of agouti expression in the livers
of various strains of mice (Fig. 2), a Northern blot containing ~2.5 µg of poly (A)+ liver RNA per lane was first
hybridized with an agouti cDNA probe. The hybridization
signals were detected with a FUJIX BAS 1000 phosphorimager and quantified with MacBAS software (Fuji Medical
Systems). The blot was then stripped and rehybridized
with a glyceraldehyde-3-phosphate dehydrogenase
(Gapd) probe and the Gapd transcript levels were quantified as described above to control for the amount of RNA
loaded for each sample. For each mRNA sample, the level
of agouti expression was reported as the ratio of agouti over
Gapd mRNA signals. The level of agouti mRNA expression
in lethal yellow mice was assigned the value of 1.0, and the
expression levels in viable yellow mice and transgenic mice
were normalized relative to this value.
Assay for functional agouti protein
Non-transgenic control mice and transgenic mice were
euthanized by cervical dislocation and the livers were
quickly excised, washed in ice-cold phosphate buffered
saline, pH 7.4 (PBS), homogenized, and stored at -80°C.
Three livers from each genotype were pooled prior to
homogenization. Liver homogenates were enriched for
agouti protein as follows. Liver homogenates (2 ml of 20
mg/ml protein) from non-transgenic control mice (negative control), from non-transgenic control mice spiked
with 33 nM recombinant agouti protein (positive
control), and from alb-agouti 86 mice, each containing 10
mM phosphoramidon, were incubated on a Nutator (4°C
for 1 hr) with 2 ml of S Sepharose cation exchange resin
equilibrated in PBS. The resin was washed with 0.5 M
NaCl in 20 mM HEPES, pH 7.5 and eluted with 1.0 M
NaCl, in 20 mM HEPES, pH 7.5. The eluants were desalted
on a PD-10 column (Pharmacia) equilibrated in PBS.

The presence of functional agouti protein in the livers of
the transgenic mice was assayed by measuring the ability
of enriched liver homogenates to inhibit the binding of
αMSH to the Mc1r. Murine melanoma B16F10 cells were
cultured and used in the [125I]-NDP-αMSH binding assay
as previously described [58,59]. B16F10 cells were incubated for 2 hr at room temperature with 0.1 nM [125I]NDP-αMSH plus increasing amounts of each of the
enriched samples described above. Cells were washed
twice with ice-cold PBS to remove free ligand before the
addition of 125 µl of scintillation cocktail. Bound radioactive ligand was measured using a Wallac 1650
Microbeta counter.
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Body weight, plasma insulin, and blood glucose analyses
Transgenic and control mice were fed a diet containing
11% fat by weight (Rodent laboratory diet 5015, PMI
Feeds), weaned at three weeks of age, and weighed every
four weeks from 4–36 weeks of age. Blood samples were
collected by retro-orbital sinus puncture from anesthetized, nonfasted, 40–50 week old male mice between 9–
11 a.m. Plasma insulin levels were measured in duplicate
by radioimmunoassay according to the manufacturer's
recommendations (ICN Biomedicals) with porcine insulin as a standard. Glucose concentrations were measured
with the One-Touch glucose determination system (Johnson & Johnson).

Mice used in the carcinogenesis studies were fed a diet
containing 4.5% fat by weight (Rodent laboratory diet
5001, PMI Feeds), weaned at three weeks of age, and
weighed every two weeks from 4–42 weeks of age.
Liver tumor analysis
Diethylnitrosamine (DEN) was purchased from Sigma
Chemical Co. A single intraperitoneal injection of DEN
(10 mg/kg) was administered to fifteen-day-old transgenic and control male mice. Groups of animals were
weighed, euthanized by cervical dislocation at 36 or 40
weeks after injection, and necropsied. The livers were
removed, weighed, and examined for visible lesions,
which were counted and measured (diameter).
Statistical analyses
All statistical analyses were performed with the JMP computer software package (SAS Institute Inc.).

List of abbreviations
alb, albumin promoter; alb-agouti mice, transgenic mice
expressing the wild-type agouti cDNA in the liver under
the regulatory control of the albumin promoter; αMSH,
α-melanocyte stimulating hormone; Avy, viable yellow
allele of the agouti gene; Ay, lethal yellow allele of the agouti
gene; DEN, diethylnitrosamine; Gapd, glyceraldehyde-3phosphate dehydrogenase; Mc1r, melanocortin 1 receptor; Mc4r, melanocortin 4 receptor; Pparg, peroxisome
proliferator activated receptor alpha; Stat1, signal transducer and activator of transcription 1; Stat3, signal transducer and activator of transcription 3; SV40, simian virus
40.
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